ciglitazone

02/01/2009 - "Ciglitazone reduces bacterial outgrowth and local inflammation at least during the early stage of S. "
01/01/2009 - "Administration of ciglitazone intranasally significantly inhibited the development of AHR, eosinophilic inflammation, and importantly, airway smooth muscle remodeling in mice chronically exposed to OVA. "
06/01/2009 - "Also, the oral administration of ciglitazone is effective in upper airway allergic inflammation in mice."
09/01/2004 - "Ciglitazone that can inhibit the inflammation of HGBEC maybe an effective treatment for acute and chronic cholecystitis."
02/01/2009 - "Because patients with type 2 diabetes have an increased risk for pneumonia, we evaluated the influence of ciglitazone, a TZD, on markers of inflammation and outcome during pneumonia caused by Streptococcus pneumoniae. "

01/01/2003 - "Because interstitial fibroblasts and glomerular mesangial cells are important cell types affected in diabetic nephropathy, the major aim of the present study was to examine the effect of ciglitazone on apoptosis and growth of renal interstitial fibroblasts (NRKs) and glomerular mesangial cells (MMCs). "
11/01/2008 - "Although PPARgamma agonists such as ciglitazone (CZ) are known to modulate diabetic nephropathy, the role of CZ in diabetes-associated HHcy and renopathy is incompletely defined. "
11/01/2008 - "Ciglitazone, a PPARgamma agonist, ameliorates diabetic nephropathy in part through homocysteine clearance."
01/01/2003 - "Ciglitazone and other thiazolidinedione compounds are peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligands and improve renal function in diabetic nephropathy independent of blood glucose control. "

02/01/2009 - "Repeated ciglitazone treatment was associated with less pulmonary inflammation, as judged by histologic examination. "
01/01/2010 - "Ciglitazone, a peroxisome proliferator-activated receptor-y (PPARy) ligand has previously been shown to attenuate lung inflammation following hemorrhagic shock. "
02/01/2009 - "Because patients with type 2 diabetes have an increased risk for pneumonia, we evaluated the influence of ciglitazone, a TZD, on markers of inflammation and outcome during pneumonia caused by Streptococcus pneumoniae. "
10/01/2008 - "We investigated the effects of ciglitazone on lung inflammation after severe hemorrhage. "
09/01/2005 - "Treatment with 9-hydroxyoctadecanoic acids and ciglitazone significantly rescued lal-/- pulmonary inflammation and aberrant gene expression. "

01/01/2010 - "Thus, our data suggest that ciglitazone, a PPARy ligand, promotes cell survival in the lung following hemorrhagic shock."
01/01/2010 - "Ciglitazone, a novel inhibitor of lung apoptosis following hemorrhagic shock."
10/01/2008 - "Ciglitazone ameliorates the inflammatory response and may reduce lung injury after hemorrhagic shock. "
01/01/2010 - "Ciglitazone, a peroxisome proliferator-activated receptor-y (PPARy) ligand has previously been shown to attenuate lung inflammation following hemorrhagic shock. "
10/01/2008 - "Ciglitazone ameliorates lung inflammation by modulating the inhibitor kappaB protein kinase/nuclear factor-kappaB pathway after hemorrhagic shock."

09/01/2004 - "Ciglitazone that can inhibit the inflammation of HGBEC maybe an effective treatment for acute and chronic cholecystitis."
10/14/2005 - "Ciglitazone inhibits the inflammation of HGBECs in vitro and has potential therapeutic effect on cholecystitis in vivo."